İlyas ÖZTÜRK
The Journal of European Internal Medicine Professionals - 2026;4(1):43-43
This letter responds to insights regarding the therapeutic benefits of finerenone beyond diabetic kidney disease. It discusses the cardiovascular and metabolic benefits of non-steroidal mineralocorticoid receptor antagonists (MRAs) and highlights the ongoing phase 3 FINE-ONE trial. This trial explores the efficacy and safety of finerenone in patients with type 1 diabetes (T1DM) and chronic kidney disease (CKD), a population that currently lacks proven therapeutic options beyond RAAS blockade and glycemic control.
